PuraPharm (HKSE:01498) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01498 PuraPharm Corporation Ltd HKSE:01498
23 GF Score
Price HK$0.28
GF Value HK$0.51
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is PuraPharm Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

HKSE:01498
23GF Score
PuraPharm Corporation Ltd HKSE:01498
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PuraPharm (HKSE:01498) Overvalued in 2026?

Based on GuruFocus' analysis, PuraPharm stock appears to be undervalued. The current stock price of HK$0.28 is trading 45.1% below its estimated GF Value™ of HK$0.51. GuruFocus considers PuraPharm to be Possible Value Trap.

Key valuation signals for HKSE:01498:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: HK$0.51 vs. price of HK$0.28 (45.1% below fair value)
  • GF Score™: 23/100 with 4 warning signs

No single metric tells the full story. See the HKSE:01498 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PuraPharm Business Description

Address Phase One, Unit 201-207, 2nd Floor, Wireless Centre, Hong Kong Science Park, New Territories, Pak Shek Kok, Tai Po, Hong Kong, HKG
PuraPharm Corporation Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, production, and sale of concentrated Chinese medicine granules (CCMG) and other Chinese healthcare products. Its operations also include the cultivation and trading of raw Chinese herbs, the manufacture and sale of traditional Chinese medicine (TCM) decoction pieces, and the provision of Chinese medical diagnostic services. The Group's reportable operating segments are: China CCMG, Hong Kong CCMG, Chinese healthcare products, Clinics, and Plantation. Maximum revenue is derived from the Hong Kong CCMG segment. Geographically, the Group generates maximum revenue from Hong Kong, and the rest from the Chinese Mainland and other countries.
23GF Score

Get the complete analysis for HKSE:01498

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.28
Price
HK$0.51
GF Value